Back to News
Market Impact: 0.25
Novo Nordisk Reports 25% Weight Loss With CagriSema In Women; Stock Up
Source: Nasdaq
Healthcare & Biotech
Novo Nordisk reported two post hoc analyses of its Phase 3 REDEFINE 1 trial in which investigational CagriSema was associated with average weight loss of 25% at Week 68 among women with overweight or obesity, versus 3% with placebo. The report concerns post hoc findings for an investigational treatment; no stock reaction was provided.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.35
Ticker Sentiment
NVO0.65
More News
- Novo Nordisk stock rises as CagriSema delivers 25% weight loss in women
- Factbox-Anthropic’s public benefit fund and how it compares with other big philanthropic efforts
- A top medical technology stock is trading at a big discount. Here's why I'm buying
- Obsessed with CoreWeave and the AI trade? You're missing out on some great stocks
- UnitedHealthcare and Humana are ending Medicare Advantage plans for nearly 1 million people
- Why is Intuitive Surgical stock sliding today?